NLRP3 and colitis: In conclusion, our study demonstrated that oral administration of SM934 exerted therapeutic effects in experimental colitis induced by TNBS via inhibiting the IECs’ apoptosis and blocking the caspase-1-mediated pyroptosis-associated NLRP3/NF-κB/MAPK signal pathways.